Infertility is one of the great challenges of modern healthcare. It afflicts about 8-12% of reproductive-aged couples worldwide, but the prevalence is even higher in industrialized countries. In 50% of cases, a male factor of infertility underlies the problem, but in about 30% of these cases the etiology of male infertility remains unknown. This eventuality, called idiopathic infertility, requires empirical medical therapy and/or assisted reproductive techniques. AREAS COVERED: This article reviews the literature about the medical treatments available for idiopathic male infertility. These treatments can be divided into two main categories: hormonal therapies and non-hormonal therapies. The compounds with the strongest evidence of efficacy and the most used in clinical practice for the treatment of idiopathic male infertility are follicle-stimulating hormone (FSH) and estrogen receptor selective modulators (SERMs). Non-hormonal treatments include a series of compounds with antioxidant and prokinetic properties, supported by variable degrees of evidence of clinical efficacy. EXPERT OPINION: Patients with idiopathic infertility have peculiar clinical features that differentiate them from each other. Therapy must, therefore, be personalized to each patient. Furthermore, scientific research must investigate the pathophysiological mechanisms that underlie infertility; only in this way, new targeted therapies can be developed.
|Titolo:||Current and emerging medical therapeutic agents for idiopathic male infertility|
|Data di pubblicazione:||2019|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|422_Duca_Expert Opin Pharmacother_2019.pdf||Documento in Pre-print||Administrator|